Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRDye800CW-nimotuzumab
- Development stage
- Phase 2
- Lead developer
- University of Saskatchewan
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Injection
01
Overview
**IRDye800CW-nimotuzumab** is an investigational near-infrared fluorescence imaging immunoconjugate developed for fluorescence-guided cancer surgery. It consists of the humanized anti-EGFR monoclonal antibody nimotuzumab covalently labeled with the near-infrared fluorescent dye IRDye 800CW. After intravenous administration, the nimotuzumab component binds EGFR on tumor cells, enabling intraoperative near-infrared visualization of EGFR-expressing tissue. The University of Saskatchewan is evaluating the agent in a Phase 1/2 study for image-guided resection of lung cancer.
- Other names
- IRDye800CW-labeled nimotuzumabIRDye-800CW-labeled nimotuzumabIRDye 800CW-labeled nimotuzumabnimotuzumab-IRDye800CWnimotuzumab-IRDye-800CWnimotuzumab-IRDye 800CW
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on IRDye800CW-nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRDye800CW-nimotuzumab.